In this webinar, Bhavesh Patel and Shrinidhi Chakravarthy of CRA’s Life Sciences Consulting Practice explored how a customized approach could help rare disease (RD) companies identify and maintain RD patients unlocking the true potential of the product and optimizing performance. CRA presented an integrated approach on Market Sizing, Patient Finding, and Patient Tracking for successful RD asset commercialization, which applies at various stages from opportunity assessment and clinical development to commercialization and lifecycle management.
Part 2: Low-priced oncology disruptors: The cuckoo in the PD-1/PD-L1 nest or the runt of the clutch?
Healthcare coverage is heterogeneous across emerging markets, with public funding limited by budgetary constraints. This typically sees higher-priced drugs,...